Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 18, 2000, Pages 3288-3294

  Zamboni, William C ^a   Egorin, Merrill J M ^a   Van Echo, David A V ^a   Day, Roger S D ^a   Meisenberg, Barry R M ^a   Brooks, Sandra E ^a   Doyle, L Austin ^a   Nemieboka, Noble N ^a   Dobson, Jason M ^a   Tait, Nancy S ^a   Tkaczuk, Katherine H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METABOLISM; MALE; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT;

EID: 0034666180     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.18.3288     Document Type: Article

References (37)

1. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
2. Cancer of the Breast: Malignant Tumors of the Breast
3. Therapeutic drug monitoring opportunities in cancer therapy
4. Drug interactions with the taxanes
5. Clinically relevant drug-drug interactions in oncology
6. Docetaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer
7. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans
8. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs
9. Taxotere safety in patients with impaired liver function (LF)
10. A phase I and pharmacokinetic (PK) study of docetaxel in cancer patients (PTS) with liver dysfunction due to malignancies
11. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
12. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function
13. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
14. Topoisomerase I interactive drugs in children with cancer
15. Phenytoin alters the disposition of topotecan and N-desmethyl metabolite in a patient with medulloblastoma
16. Topotecan is a cytochrome P450-3A inhibitor: Clinical and pharmacologic evidence
17. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
18. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography
19. A new docetaxel solid-phase extraction procedure in human plasma for pharmacokinetics determination
20. High-performance liquid chromatographic determination of the novel antitumor drug topotecan and topotecan as the total of the lactone plus carboxylate forms in human plasma
21. Escalating systemic exposure to topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia
22. Evaluation of the linearity of docetaxel pharmacokinetics
23. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group Study
24. Predicting drug interactions in vivo from experiments in vitro: Human studies with paclitaxel and ketoconazole
25. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
26. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
27. Influence of liver function on drug distribution
28. Doxorubicin (DOX) and Taxotere (TXT): A pharmacokinetic study of the combination in advanced breast cancer
29. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) and doxorubicinol (Dx-ol)
30. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
31. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
32. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors
33. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
34. Phase I and pharmacokinetic study of taxotere given as a short intravenous infusion